Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 2.82
(-0.7%)
CNY 2.82
(-0.7%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 16.7 Billion CNY | -8.85% |
| 2022 | 18.33 Billion CNY | -30.56% |
| 2021 | 26.39 Billion CNY | -15.64% |
| 2020 | 31.29 Billion CNY | -3.62% |
| 2019 | 32.46 Billion CNY | -6.81% |
| 2018 | 34.83 Billion CNY | 29.1% |
| 2017 | 26.98 Billion CNY | 72.34% |
| 2016 | 15.65 Billion CNY | 76.68% |
| 2015 | 8.86 Billion CNY | 56.06% |
| 2014 | 5.67 Billion CNY | 27.48% |
| 2013 | 4.45 Billion CNY | 42.75% |
| 2012 | 3.12 Billion CNY | 40.71% |
| 2011 | 2.21 Billion CNY | 49.89% |
| 2010 | 1.47 Billion CNY | 42.26% |
| 2009 | 1.03 Billion CNY | 45.34% |
| 2008 | 715.52 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 15.55 Billion CNY | -6.88% |
| 2024 Q2 | 15.72 Billion CNY | 1.07% |
| 2024 Q3 | 16.41 Billion CNY | 4.41% |
| 2023 Q3 | 17.42 Billion CNY | -4.67% |
| 2023 FY | 16.7 Billion CNY | -8.85% |
| 2023 Q4 | 16.7 Billion CNY | -4.12% |
| 2023 Q2 | 18.28 Billion CNY | -4.74% |
| 2023 Q1 | 19.18 Billion CNY | 4.68% |
| 2022 Q1 | 27.52 Billion CNY | 4.27% |
| 2022 FY | 18.33 Billion CNY | -30.56% |
| 2022 Q4 | 18.33 Billion CNY | -22.94% |
| 2022 Q3 | 23.78 Billion CNY | -7.74% |
| 2022 Q2 | 25.78 Billion CNY | -6.32% |
| 2021 FY | 26.39 Billion CNY | -15.64% |
| 2021 Q4 | 26.39 Billion CNY | -8.55% |
| 2021 Q2 | 29.47 Billion CNY | -8.91% |
| 2021 Q3 | 28.86 Billion CNY | -2.09% |
| 2021 Q1 | 32.36 Billion CNY | 3.43% |
| 2020 Q3 | 33.37 Billion CNY | 0.49% |
| 2020 FY | 31.29 Billion CNY | -3.62% |
| 2020 Q1 | 34.17 Billion CNY | 5.27% |
| 2020 Q2 | 33.2 Billion CNY | -2.84% |
| 2020 Q4 | 31.29 Billion CNY | -6.23% |
| 2019 Q2 | 37.59 Billion CNY | 1.75% |
| 2019 Q4 | 32.46 Billion CNY | -12.81% |
| 2019 Q3 | 37.23 Billion CNY | -0.97% |
| 2019 FY | 32.46 Billion CNY | -6.81% |
| 2019 Q1 | 36.95 Billion CNY | 6.07% |
| 2018 Q4 | 34.83 Billion CNY | 0.27% |
| 2018 Q3 | 34.74 Billion CNY | 4.91% |
| 2018 Q2 | 33.11 Billion CNY | 13.74% |
| 2018 Q1 | 29.11 Billion CNY | 7.91% |
| 2018 FY | 34.83 Billion CNY | 29.1% |
| 2017 Q1 | 18.24 Billion CNY | 16.54% |
| 2017 Q3 | 23.34 Billion CNY | 15.8% |
| 2017 Q4 | 26.98 Billion CNY | 15.57% |
| 2017 FY | 26.98 Billion CNY | 72.34% |
| 2017 Q2 | 20.16 Billion CNY | 10.5% |
| 2016 Q1 | 10.28 Billion CNY | 16.07% |
| 2016 FY | 15.65 Billion CNY | 76.68% |
| 2016 Q4 | 15.65 Billion CNY | 2.27% |
| 2016 Q3 | 15.3 Billion CNY | 38.67% |
| 2016 Q2 | 11.04 Billion CNY | 7.34% |
| 2015 Q3 | 7.93 Billion CNY | 7.31% |
| 2015 FY | 8.86 Billion CNY | 56.06% |
| 2015 Q2 | 7.39 Billion CNY | 10.08% |
| 2015 Q4 | 8.86 Billion CNY | 11.66% |
| 2015 Q1 | 6.71 Billion CNY | 18.32% |
| 2014 Q3 | 5.12 Billion CNY | 2.96% |
| 2014 Q1 | 4.74 Billion CNY | 6.62% |
| 2014 FY | 5.67 Billion CNY | 27.48% |
| 2014 Q4 | 5.67 Billion CNY | 10.72% |
| 2014 Q2 | 4.98 Billion CNY | 4.9% |
| 2013 Q3 | 3.94 Billion CNY | 8.95% |
| 2013 Q4 | 4.45 Billion CNY | 12.83% |
| 2013 Q2 | 3.62 Billion CNY | 2.25% |
| 2013 FY | 4.45 Billion CNY | 42.75% |
| 2013 Q1 | 3.54 Billion CNY | 13.56% |
| 2012 Q4 | 3.12 Billion CNY | 1.64% |
| 2012 Q3 | 3.07 Billion CNY | 15.55% |
| 2012 Q1 | 2.61 Billion CNY | 18.05% |
| 2012 Q2 | 2.65 Billion CNY | 1.5% |
| 2012 FY | 3.12 Billion CNY | 40.71% |
| 2011 Q3 | 2.19 Billion CNY | 3.2% |
| 2011 Q4 | 2.21 Billion CNY | 0.85% |
| 2011 Q1 | 1.49 Billion CNY | 1.11% |
| 2011 Q2 | 2.13 Billion CNY | 42.43% |
| 2011 FY | 2.21 Billion CNY | 49.89% |
| 2010 Q4 | 1.47 Billion CNY | 0.0% |
| 2010 FY | 1.47 Billion CNY | 42.26% |
| 2009 FY | 1.03 Billion CNY | 45.34% |
| 2008 FY | 715.52 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 48.26 Billion CNY | 65.378% |
| Shenzhen Glory Medical Co.,Ltd. | 3.93 Billion CNY | -324.987% |